The utility of iron chelators in the management of inflammatory disorders

C. Lehmann; S. Islam; S. Jarosch; J. Zhou; D. Hoskin; A. Greenshields; N. Al-Banna; N. Sharawy; A. Sczcesniak; M. Kelly; K. Wafa; W. Cheliak; B. Holbein

doi:10.1155/2015/516740

The utility of iron chelators in the management of inflammatory disorders

C. Lehmann, S. Islam, S. Jarosch, J. Zhou, D. Hoskin, A. Greenshields, N. Al-Banna, N. Sharawy, A. Sczcesniak, M. Kelly, K. Wafa, W. Cheliak, B. Holbein

Research output: Contribution to journal › Review article › peer-review

47 Citations (Scopus)

Abstract

Since iron can contribute to detrimental radical generating processes through the Fenton and Haber-Weiss reactions, it seems to be a reasonable approach to modulate iron-related pathways in inflammation. In the human organism a counterregulatory reduction in iron availability is observed during inflammatory diseases. Under pathological conditions with reduced or increased baseline iron levels different consequences regarding protection or susceptibility to inflammation have to be considered. Given the role of iron in development of inflammatory diseases, pharmaceutical agents targeting this pathway promise to improve the clinical outcome. The objective of this review is to highlight the mechanisms of iron regulation and iron chelation, and to demonstrate the potential impact of this strategy in the management of several acute and chronic inflammatory diseases, including cancer.

Original language	English
Article number	516740
Journal	Mediators of Inflammation
Volume	2015
DOIs	https://doi.org/10.1155/2015/516740
Publication status	Published - 2015

Bibliographical note

Publisher Copyright:
© 2015 C. Lehmann et al.

ASJC Scopus Subject Areas

Immunology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1155/2015/516740

Cite this

@article{ea93bf9cc6574161884162f7441ef506,

title = "The utility of iron chelators in the management of inflammatory disorders",

abstract = "Since iron can contribute to detrimental radical generating processes through the Fenton and Haber-Weiss reactions, it seems to be a reasonable approach to modulate iron-related pathways in inflammation. In the human organism a counterregulatory reduction in iron availability is observed during inflammatory diseases. Under pathological conditions with reduced or increased baseline iron levels different consequences regarding protection or susceptibility to inflammation have to be considered. Given the role of iron in development of inflammatory diseases, pharmaceutical agents targeting this pathway promise to improve the clinical outcome. The objective of this review is to highlight the mechanisms of iron regulation and iron chelation, and to demonstrate the potential impact of this strategy in the management of several acute and chronic inflammatory diseases, including cancer.",

author = "C. Lehmann and S. Islam and S. Jarosch and J. Zhou and D. Hoskin and A. Greenshields and N. Al-Banna and N. Sharawy and A. Sczcesniak and M. Kelly and K. Wafa and W. Cheliak and B. Holbein",

note = "Publisher Copyright: {\textcopyright} 2015 C. Lehmann et al.",

year = "2015",

doi = "10.1155/2015/516740",

language = "English",

volume = "2015",

journal = "Mediators of Inflammation",

issn = "0962-9351",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The utility of iron chelators in the management of inflammatory disorders

AU - Lehmann, C.

AU - Islam, S.

AU - Jarosch, S.

AU - Zhou, J.

AU - Hoskin, D.

AU - Greenshields, A.

AU - Al-Banna, N.

AU - Sharawy, N.

AU - Sczcesniak, A.

AU - Kelly, M.

AU - Wafa, K.

AU - Cheliak, W.

AU - Holbein, B.

PY - 2015

Y1 - 2015

N2 - Since iron can contribute to detrimental radical generating processes through the Fenton and Haber-Weiss reactions, it seems to be a reasonable approach to modulate iron-related pathways in inflammation. In the human organism a counterregulatory reduction in iron availability is observed during inflammatory diseases. Under pathological conditions with reduced or increased baseline iron levels different consequences regarding protection or susceptibility to inflammation have to be considered. Given the role of iron in development of inflammatory diseases, pharmaceutical agents targeting this pathway promise to improve the clinical outcome. The objective of this review is to highlight the mechanisms of iron regulation and iron chelation, and to demonstrate the potential impact of this strategy in the management of several acute and chronic inflammatory diseases, including cancer.

AB - Since iron can contribute to detrimental radical generating processes through the Fenton and Haber-Weiss reactions, it seems to be a reasonable approach to modulate iron-related pathways in inflammation. In the human organism a counterregulatory reduction in iron availability is observed during inflammatory diseases. Under pathological conditions with reduced or increased baseline iron levels different consequences regarding protection or susceptibility to inflammation have to be considered. Given the role of iron in development of inflammatory diseases, pharmaceutical agents targeting this pathway promise to improve the clinical outcome. The objective of this review is to highlight the mechanisms of iron regulation and iron chelation, and to demonstrate the potential impact of this strategy in the management of several acute and chronic inflammatory diseases, including cancer.

UR - http://www.scopus.com/inward/record.url?scp=84926677022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926677022&partnerID=8YFLogxK

U2 - 10.1155/2015/516740

DO - 10.1155/2015/516740

M3 - Review article

C2 - 25878400

AN - SCOPUS:84926677022

SN - 0962-9351

VL - 2015

JO - Mediators of Inflammation

JF - Mediators of Inflammation

M1 - 516740

ER -

The utility of iron chelators in the management of inflammatory disorders

Abstract

Bibliographical note

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this